Newsroom

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST).

By |2020-04-28T13:52:38-04:00April 28th, 2020|News|

Conversations with the Life Raft Group LIVE

Conversations with the Life Raft Group will debuted 4/2/2020 at 1 pm. Our first featured guest was Norman J. Scherzer, the Executive Director of the Life Raft Group. With his background at the CDC as Assistant Commissioner of Health for NYC, Norman is an excellent resource for discussing strategies for coping with COVID-19.

By |2020-07-09T17:49:22-04:00April 2nd, 2020|GIST Education, Patient Support, Webcast|
Go to Top